VRNA News and Press, Verona Pharma plc From 12/30/23

2023-12-30 06:50:00 ET Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be monster winners in 2024. H...

2023-12-29 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-18 02:54:02 ET Summary Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Their main candidate drug, ensifentrine, has shown promising results in clinical trials for COPD, cystic fibrosis, a...

LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognitio...

LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 2023: Jefferies London Hea...

Verona Pharma plc (VRNA) is expected to report $-0.27 for Q3 2023

2023-11-04 11:58:02 ET Verona Pharma plc (VRNA) Q3 2023 Results Conference Call November 02, 2023 09:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hahn - CFO Dr. Kathy Rickard - Chief Medical Officer Chris Martin - SVP, Commercial Confe...

2023-11-02 03:22:42 ET More on Verona Pharma Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon Verona Pharma: Financial Health And COPD Market Impact 2024 Verona Pharma: Targeting The Large COPD Market Verona Pharma granted FDA review fo...

US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT LONDON and RALEIG...

2023-10-20 17:24:19 ET Gainers: Day One Biopharmaceuticals ( DAWN ) +6% . ContextLogic  ( WISH ) +5% . Vital Farms ( VITL ) +5% . Verona Pharma  ( VRNA ) +4% . GoPro ( GPRO ) +3% . Losers: IGM Biosciences ( IG...